Encompass Health (NYSE:EHC – Get Rating) had its price objective decreased by stock analysts at Stephens from $78.00 to $74.00 in a research note issued on Tuesday, The Fly reports. Stephens’ target price would indicate a potential upside of 31.18% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Truist Financial raised their target price on Encompass Health from $78.00 to $85.00 in a report on Thursday, April 7th. Royal Bank of Canada dropped their price target on Encompass Health from $85.00 to $82.00 in a research report on Wednesday, June 8th. Credit Suisse Group dropped their price target on Encompass Health from $83.00 to $82.00 and set an “outperform” rating for the company in a research report on Friday, June 10th. Raymond James dropped their price target on Encompass Health from $85.00 to $70.00 in a research report on Friday. Finally, TheStreet upgraded Encompass Health from a “c+” rating to a “b-” rating in a research report on Tuesday, March 15th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $79.56.
Encompass Health stock opened at $56.41 on Tuesday. Encompass Health has a one year low of $53.56 and a one year high of $85.75. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.26. The business has a fifty day moving average of $64.98 and a two-hundred day moving average of $65.41. The company has a market cap of $5.63 billion, a P/E ratio of 14.43, a price-to-earnings-growth ratio of 1.88 and a beta of 0.96.
In other news, Director Kevin J. O’connor acquired 1,000 shares of Encompass Health stock in a transaction dated Friday, May 6th. The shares were acquired at an average cost of $66.48 per share, with a total value of $66,480.00. Following the purchase, the director now directly owns 3,436 shares of the company’s stock, valued at approximately $228,425.28. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of EHC. Morgan Stanley increased its holdings in Encompass Health by 27.5% during the 2nd quarter. Morgan Stanley now owns 670,104 shares of the company’s stock worth $52,288,000 after purchasing an additional 144,463 shares during the last quarter. HighTower Advisors LLC increased its holdings in Encompass Health by 18.6% during the 3rd quarter. HighTower Advisors LLC now owns 3,857 shares of the company’s stock worth $290,000 after purchasing an additional 605 shares during the last quarter. Franklin Resources Inc. increased its holdings in Encompass Health by 74.6% during the 3rd quarter. Franklin Resources Inc. now owns 4,661 shares of the company’s stock worth $350,000 after purchasing an additional 1,992 shares during the last quarter. Gotham Asset Management LLC purchased a new stake in Encompass Health during the 3rd quarter worth approximately $279,000. Finally, MML Investors Services LLC increased its holdings in Encompass Health by 11.9% during the 3rd quarter. MML Investors Services LLC now owns 6,638 shares of the company’s stock worth $498,000 after purchasing an additional 706 shares during the last quarter. Institutional investors own 91.70% of the company’s stock.
About Encompass Health (Get Rating)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- Quest Diagnostic Stock is Ready to Move Higher
- MarketBeat Podcast: How To Navigate The Market Downturn Like A Pro
- Cracks Form In Adobe’s Growth Outlook
- Chewy Stock is Not All Bark and No Bite
- PEG Ratio Pegs These 3 Stocks as Long-Term Buys
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.